ALDX
Companies
NASDAQ
Aldeyra Therapeutics Inc.
Health Care
$3.17
-$1.82 (-36.47%)
Price Chart
Overview
About ALDX
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Market Cap
$229.3M
Volume
15.0M
Avg. Volume
6.5M
P/E Ratio
-2.8877048
Dividend Yield
0.00%
Employees
14.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.59
High Correlation
Volatility
High (0.83)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ALDX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$229.3M
Volume15.0M
P/E Ratio-2.89
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 1, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025